Previous Close | 8.18 |
Open | 8.28 |
Bid | 0.00 x 4000 |
Ask | 0.00 x 800 |
Day's Range | 8.22 - 8.66 |
52 Week Range | 3.92 - 26.60 |
Volume | |
Avg. Volume | 1,542,240 |
Market Cap | 1.6B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.13 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for SANA
Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-squeeze stocks in an effort to move the equities higher, forcing the bears to cover their short positions. Of course, short covering raises the prices of the affected securities, ultimately creating a bullish bonanza. Throughout this list of short-squeeze stocks, I will refer to two concepts. The firs
Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as research prioritization Expect to file INDs this year for SC291 and SG295 Presented preclinical data showing survival of transplanted hypoimmune allogeneic pancreatic islet cells, cardiomyocytes, and retinal pigment epithelium cells without immunosuppression in non-human primates Q2 2022 cash positi
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic immune response and autoimmune response in a type 1 diabetes mouse model Transplanting allogeneic cells into a non-human primate without immune suppression represents a key step toward development of en